Granted Patent B2

US 12,486,261 · App. 18/662,990 · Granted Dec 2, 2025

Inventors: Corey Reeves (Foster City, CA); F. Anthony Romero (Redwood City, CA); Christopher T. Jones (Foster City, CA); Martijn Fenaux (San Mateo, CA); Gary W. Luehr (Foster City, CA)

Assignee: Terns Pharmaceuticals, Inc.

C07D413/14A61K9/0019A61P1/16C07D417/14

Abstract

Claims (84)

1 . A compound of formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

X is N or CH;

Y is N or CR 4 ;

n is 0 or 1;

R is hydrogen;

R 1 is —C 1 -C 6 alkylene-R 5 ;

R 2 is hydrogen, oxo, or C 1 -C 6 alkyl;

R 3 is hydrogen, oxo, or C 1 -C 6 alkyl and R 4 is hydrogen, OH, or C 1 -C 6 alkyl,

or R 3 and R 4 are taken together with the carbon atoms to which they are attached to form C 3 -C 6 cycloalkyl optionally substituted by halo or C 1 -C 3 alkyl;

R 5 is 3- to 6-membered heterocyclyl or 5- to 6-membered heteroaryl, wherein the 3- to 6-membered heterocyclyl or 5- to 6-membered heteroaryl of R 5 is independently optionally substituted by halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkenyl, or C 1 -C 6 haloalkyl;

R 7 is selected from the group consisting of

or R 7 is —C(O)NH—R 8 , wherein R 8 is hydrogen, —OH, —S(O) 2 —C 1 -C 6 alkyl, or —C 1 -C 6 alkyl optionally substituted by halo;

Ring A is 6-membered heteroaryl optionally substituted by halo, oxo, —CN, C 3 -C 6 cycloalkyl, or C 1 -C 6 alkyl optionally substituted by halo or OH;

L is a bond, —O—, C 1 -C 6 alkylene, *—O—C 1 -C 6 alkylene-**, *—C 1 -C 6 alkylene-O—**, or *—NR 6 —C 1 -C 6 alkylene-**, wherein:

represents the point of attachment to ring A and ** represents the point of attachment to ring B;

when L is *—O—C 1 -C 6 alkylene-**, the C 1 -C 6 alkylene is optionally substituted by R L ,

wherein each R L is independently C 1 -C 6 alkyl or halo, or two R L are taken together with the carbon atom or atoms to which they are attached to form C 3 -C 6 cycloalkyl or 3- to 6-membered heterocyclyl; and

when L is C 1 -C 6 alkylene, the C 1 -C 6 alkylene is optionally substituted by R L 1, wherein

each R L1 is independently halo, OH, oxo, or C 1 -C 6 alkyl, or two R L1 are taken together with the carbon atom or atoms to which they are attached to form C 3 -C 6 cycloalkyl or 3- to 6-membered heterocyclyl;

R 6 is hydrogen or C 1 -C 6 alkyl; and

Ring B is C 3 -C 10 cycloalkyl, C 6 -C 14 aryl, 4- to 12-membered heterocyclyl, or 5- to 12-membered heteroaryl, each of which is independently optionally substituted by one to three substituents independently selected from the group consisting of halo, CN, oxo, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —C(O) CH 3 , —C(O)NH 2 , —S(O) 2 CH 3 , cyclopropyl, and phenyl, with the proviso that:

when R 7 is —C(O)NH—R 8 , R 1 is

X is N, Y is CH, n is 1, R 2 and R 3 are each hydrogen, ring A is 6-membered heteroaryl, and L is *—OCH 2 —**, then ring B is not

2 . The compound of claim 1 , wherein the compound is of Formula I-s:

or a pharmaceutically acceptable salt thereof.

3 . The compound of claim 1 , wherein the compound is of Formula I-t:

or a pharmaceutically acceptable salt thereof.

4 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

n is 1;

X is N;

R 2 is hydrogen;

R 5 is an optionally substituted five-membered heteroaryl comprising one or two heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur, or an optionally substituted four-membered heterocycle comprising one oxygen atom;

R 7 is

—C(O)NHCH 3 , —C(O)NH 2 , C(O)NHCH 2 CF 3 , C(O)NHS(O) 2 CH 3 , or C(O)NHOH;

Ring A is an optionally substituted 6-membered heteroaryl;

L is a bond or *—O—CH 2 —**; and

Ring B is phenyl optionally substituted by one to three substituents independently selected from the group consisting of halo and cyano.

5 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is —CH 2 —R 5 .

6 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is 4-membered heterocyclyl comprising one oxygen atom optionally substituted by halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkenyl, or C 1 -C 6 haloalkyl.

7 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is

optionally substituted by halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkenyl, or C 1 -C 6 haloalkyl.

8 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is

9 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is 5-membered heteroaryl optionally substituted by halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkenyl, or C 1 -C 6 haloalkyl.

10 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is

optionally substituted by halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkenyl, or C 1 -C 6 haloalkyl.

11 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is

optionally substituted by halo C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkenyl, or C 1 -C 6 haloalkyl.

12 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is

13 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is N.

14 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein n is 1.

15 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Y is N.

16 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Y is CR 4 .

17 . The compound of claim 16 , or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 are taken together with the carbon atoms to which they are attached to form a cyclopropyl group.

18 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is selected from the group consisting of

19 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is

20 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is

21 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is

22 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is

23 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is

24 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is —C(O)NH—R 8 .

25 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 8 is hydrogen.

26 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 8 is —OH.

27 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 8 is —S(O) 2 —C 1 -C 6 alkyl.

28 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 8 is —S(O) 2 CH 3 .

29 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 8 is —C 1 -C 6 alkyl optionally substituted by halo.

30 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 8 is —C 1 -C 2 alkyl optionally substituted by halo.

31 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 8 is —CH 2 CF 3 .

32 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 8 is —CH 3 .

33 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ring A is

34 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ring A is

35 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein L is *—O—C 1 -C 6 alkylene-**.

36 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein L is *—O—CH 2 —**.

37 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ring B is C 6 aryl, which is optionally substituted by one to three substituents independently selected from the group consisting of halo and CN.

38 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ring B is C 6 aryl, which is optionally substituted by one to three substituents independently selected from the group consisting of —F, —Cl, —Br, and —CN.

39 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ring B is

40 . A compound selected from the group consisting off

or a pharmaceutically acceptable salt thereof.

41 . A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

42 . A method of treating a disease mediated by glucagon-like peptide-1 receptor (GLP-1R) in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

43 . The method of claim 42 , wherein the disease is a liver disease.

44 . The method of claim 43 , wherein the liver disease is primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), drug induced cholestasis, intrahepatic cholestasis of pregnancy, parenteral nutrition associated cholestasis (PNAC), bacterial overgrowth or sepsis associated cholestasis, autoimmune hepatitis, viral hepatitis, alcoholic liver disease, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), graft versus host disease, transplant liver regeneration, congenital hepatic fibrosis, choledocholithiasis, granulomatous liver disease, intra- or extrahepatic malignancy, Sjogren's syndrome, sarcoidosis, Wilson's disease, Gaucher's disease, hemochromatosis, or alpha-1-antitrypsin deficiency.

45 . The method of claim 42 , wherein the disease is diabetes.

46 . The method of claim 42 , wherein the disease is a cardiometabolic disease.

Assignments (3)

Continuity (3)

References Cited (246)